Camurus announced the FDA accepted for review its resubmitted NDA for CAM2029 (octreotide), with a PDUFA target action date set for 18 Dec 2026. This is a positive procedural milestone that advances the regulatory timeline for CAM2029. No efficacy/safety or financial impact details were provided in the excerpt.
Camurus announced the FDA accepted for review its resubmitted NDA for CAM2029 (octreotide), with a PDUFA target action date set for 18 Dec 2026. This is a positive procedural milestone that advances the regulatory timeline for CAM2029. No efficacy/safety or financial impact details were provided in the excerpt.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
